WESTERN ASSOCIATION OF GYNECOLOGIC ONCOLOGISTS (WAGO)

WAGO Annual Meeting June 16-18, 2011 Stein Eriksen Lodge Park City, Utah

Lymphoid Enhancing Factor 1 (Lef-1) Overexpression in Epithelial Ovarian, Fallopian Tube and Peritoneal Cancer and Associations with Clinical Factors.

Aine Clements, MD,¹ David Engle, MD,¹ Dawne Shelton, PhD,¹ Traci Neff, BS,¹ Soo Park, MD, PhD,¹ David Bender, MD,^{1,2} Amina Ahmed, MD,^{1,2} Koen DeGeest, MD,^{1,2} Anna Button, MS,³ John F. Engelhardt,⁴ PhD, Michael J Goodheart, MD^{1,2}

Objective: Lymphoid enhancing factor-1 (Lef-1) is a transcription factor and downstream target of Wnt\β-catenin signaling. Dysregulation of the Wnt\Bcatenin\Lef-1 signaling pathway has been implicated in cancer formation. hypothesize We that Lef-1 is overexpressed in ovarian, fallopian tube peritoneal cancers, and and is associated with adverse clinical and pathologic factors.

Methods: Using our divisional database we identified patients diagnosed with epithelial ovarian, fallopian tube and/or primary peritoneal cancer. Lef-1 mRNA levels were determined in tumor tissue using Real Time (RT) PCR, and p53 mutations were determined by direct sequencing. Clinical data included age at diagnosis, history, recurrence sensitivity. platinum grade. stage. cytoreduction, histology. degree of additional p53 mutational status, and follow up that were collected from a retrospective chart review. Lef-1 mRNA levels were compared to clinical and pathological data using ANOVA, chi square analysis and survival was analyzed using the log rank test.

Results: We identified 51 patients with ovarian, fallopian tube or peritoneal carcinoma. Lef-1 mRNA levels were significantly elevated in tumor samples compared non-cancerous when to (p=0.0001). Elevated Lef-1 controls mRNA levels significantly were associated with advanced stage (p=0.04), and serous histology (p=0.01).

¹Department of Obstetrics & Gynecology, ²Holden Comprehensive Cancer Center, ³Department of Biostatistics, ⁴Department of Anatomy and Cell Biology, The University of Iowa, Iowa City, Iowa 52242

Corresponding author: Michael Goodheart, Department of Obstetrics and Gynecology, University of Iowa, 3234 MERF, 200 Hawkins Drive, Iowa City, IA, 52242. Telephone(319) 335-2015 <u>michael-goodheart@uiowa.edu</u>

1

This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Proceedings in Obstetrics and Gynecology, 2011 July; 2(1):9 WESTERN ASSOCIATION OF GYNECOLOGIC ONCOLOGISTS (WAGO)

WAGO Annual Meeting June 16-18, 2011 Stein Eriksen Lodge Park City, Utah

Patients with a greater than or equal to 2.5 fold increase in Lef-1 mRNA expression had an overall survival of 28% compared to a 57% five year overall survival for patients with less than a 2.5 fold increase (p=0.08).

Conclusions: Lef-1 mRNA levels were statistically elevated in cases of ovarian, fallopian tube or peritoneal cancer when

compared to non-cancerous controls. Among cancer cases, levels of Lef-1 were statistically different between stage and histology. Lef-1 overexpression may be predictive of poor overall survival. These findings suggest that Lef-1 overexpression may contribute to ovarian, fallopian tube and peritoneal carcinogenesis, and that further investigation is warranted.

LEF-1 in Ovarian, Fallopian Tube and Peritoneal Cancer

Meeting Abstracts Department of Obstetrics and Gynecology University of Iowa, Iowa City, IA